RECRO PHARMA INC's ticker is REPH and the CUSIP is 75629F109. A total of 70 filers reported holding RECRO PHARMA INC in Q4 2020. The put-call ratio across all filers is 1.67 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,097 | -57.4% | 13,000 | 0.0% | 0.00% | -57.1% |
| Q2 2023 | $14,300 | -7.6% | 13,000 | 0.0% | 0.01% | -30.0% |
| Q1 2023 | $15,470 | -20.1% | 13,000 | 0.0% | 0.01% | -9.1% |
| Q4 2022 | $19,370 | -7.8% | 13,000 | 0.0% | 0.01% | 0.0% |
| Q3 2022 | $21,000 | +110.0% | 13,000 | 0.0% | 0.01% | +120.0% |
| Q2 2022 | $10,000 | -56.5% | 13,000 | 0.0% | 0.01% | -44.4% |
| Q1 2022 | $23,000 | +4.5% | 13,000 | 0.0% | 0.01% | +12.5% |
| Q4 2021 | $22,000 | -18.5% | 13,000 | 0.0% | 0.01% | -46.7% |
| Q3 2021 | $27,000 | -6.9% | 13,000 | 0.0% | 0.02% | +15.4% |
| Q2 2021 | $29,000 | -19.4% | 13,000 | 0.0% | 0.01% | -27.8% |
| Q1 2021 | $36,000 | -2.7% | 13,000 | 0.0% | 0.02% | -5.3% |
| Q4 2020 | $37,000 | +37.0% | 13,000 | 0.0% | 0.02% | +11.8% |
| Q3 2020 | $27,000 | -54.2% | 13,000 | 0.0% | 0.02% | -60.5% |
| Q2 2020 | $59,000 | -44.3% | 13,000 | 0.0% | 0.04% | -57.4% |
| Q1 2020 | $106,000 | – | 13,000 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Athyrium Capital Management, LP | 2,202,420 | $6,145,000 | 3.11% |
| Samjo Capital LLC | 560,000 | $1,562,000 | 1.16% |
| MAK CAPITAL ONE LLC | 1,224,264 | $3,416,000 | 0.81% |
| Cowen Prime Services LLC | 470,500 | $1,313,000 | 0.50% |
| Portolan Capital Management | 1,957,283 | $5,461,000 | 0.43% |
| Parkman Healthcare Partners LLC | 601,967 | $1,679,000 | 0.39% |
| Rubric Capital Management LP | 1,076,587 | $3,004,000 | 0.18% |
| Frontier Wealth Management LLC | 49,112 | $2,142,000 | 0.16% |
| ESSEX INVESTMENT MANAGEMENT CO LLC | 466,992 | $1,303,000 | 0.16% |
| AWM Investment Company, Inc. | 391,304 | $1,092,000 | 0.12% |